◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Cipla Limited (CIPLA) EPS 2023–TTM

Name: Cipla Limited (CIPLA) eps history 2023-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-01

Cipla Limited annual earnings per share (EPS) for fiscal TTM was ₹35.83, a decrease of 25.4% from ₹48.00 in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

CIPLA Annual EPS

EPS (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Diluted EPS	₹36M	₹48M	₹65M	₹51M	₹35M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CIPLA Quarterly EPS

EPS (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Diluted EPS	₹11M	₹10M	₹7M	₹8M	—	₹16M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EPS at Comparable Companies

4151 EPS — Kyowa Kirin Co., Ltd.
LAURUSLABS EPS — Laurus Labs Limited
ZYDUSLIFE EPS — Zydus Lifesciences Limited
DRREDDY EPS — Dr. Reddy's Laboratories Limited
AUROPHARMA EPS — Aurobindo Pharma Limited
MANKIND EPS — Mankind Pharma Limited

More CIPLA metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow

All CIPLA financial statements → Interactive CIPLA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.